UNSPSC 51152102: Atropine/hyoscyamine/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.

UNSPSC 51152102 Atropine/hyoscyamine/phenobarbital is a Commodity code that encompasses pharmaceutical products and related delivery systems state and local governments procure for community health, emergency response, and substance-abuse mitigation programs. Recent activity shows the code capturing acquisitions of opioid-reversal medications and drug-deactivation systems, alongside exploratory procurement for direct-to-manufacturer pharmacy benefit arrangements. State and local health agencies and human services departments are the primary issuing bodies, with Seminole County, Florida and the Texas Health and Human Services Commission appearing in current market activity. The underlying work involves procurement of finished pharmaceutical inventory, negotiation of wholesale or direct-supplier relationships, and program administration for medication access and disposal.

Seminole County, Florida and Texas represent the jurisdictions with recent documented activity under this code. Seminole County issued IFB 60459723LAS on June 30, 2026, for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with a response deadline of July 26, 2023, requiring quarterly delivery to the Seminole County Community Health Building in Sanford and including a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels, signaling state interest in alternative acquisition and contracting models for pharmaceutical programs. Both opportunities reflect demand for pharmaceutical inventory management tied to public health priorities rather to clinical treatment at individual facilities.